Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The centralized marketing authorization granted by the EC is valid in all EU Member
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Subscribe To Our Newsletter & Stay Updated
